This document discusses weaning and extubation in pediatrics. It defines weaning as transitioning from ventilatory support to spontaneous breathing, and extubation as separating a patient from their ventilator. Successful weaning and extubation means maintaining effective gas exchange without mechanical support. Factors that indicate readiness for weaning include improving underlying conditions, adequate gas exchange, no undue burden on respiratory muscles, and the ability to sustain spontaneous ventilation as support decreases. Spontaneous breathing trials can assess readiness for extubation. Protocols for weaning and criteria for extubation can help optimize outcomes in pediatrics.
Differences between Paediatric and Adult airway gourav_singh
These slides contain a brief discussion about what all common differences between pediatric and adult airway can be found if you are in an ENT OPD or during Anesthesia.
Just a brief discussion.
Differences between Paediatric and Adult airway gourav_singh
These slides contain a brief discussion about what all common differences between pediatric and adult airway can be found if you are in an ENT OPD or during Anesthesia.
Just a brief discussion.
Presentation of Dr. Lluis Blanch at 10th Pulmonary Medicine Update Course, Cairo, Egypt. Pulmonary Medicine Update Course is organized by Scribe : www.scribeofegypt.com
Weaning and Discontinuing Ventilatory Supporthanaa
1) The epidemiology of weaning
2) Evidence-based weaning guidelines
3) The pathophysiology of weaning failure
4) Is there a role for different ventilator modes in weaning?
Patient ventilator interactions during mechanical ventilationDr.Mahmoud Abbas
Patient Ventilator Interaction during Mechanical Ventilation lecture presented by Dr.Lluis Blanch at Pulmonary Critical Care Egypt Meeting and Exhibition, January 2014. www.pccmegypt.com
The Changing Role of the Coronary Care Cardiologist & The Emerging Role of Ca...Dr.Mahmoud Abbas
The Changing Role of the Coronary Care Cardiologist
&
The Emerging Role of Cardiac Intensive Care Specialists lecture presented by Dr Sherif Mokhtar, President ECCCP at the Egyptian Spanish Critical care Symposium held at Cairo, Egypt on 11 May 2023
Drug induced Kidney Injury in the ICU. Presentation by Dr Sandra Kane Gill , President Society of Critical Care Medicine (SCCM) , USA at the Egyptian Critical care Summit 2022 conference , organized by the Egyptian College of Critical care Physicians (ECCCP) , Egypt
Using Novel Kidney Biomarkers to Guide Drug Therapy.pdfDr.Mahmoud Abbas
Using Novel Kidney Biomarkers to Guide Drug Therapy: Presentation by Dr Sandra Gill , President SCCM at the Egyptian Critical Care Summit 2022 held at Cairo, Egypt and organized by the Egyptian College of Critical care Physicians (ECCCP)
Presentation by Dr Marwa Atef , National Research Center, Cairo, Egypt . Presented at Cairo Textile Week 2021 , the leading textiles conference in Egypt
Cairo Textile Week 2021 Conference -Egypt Textiles & Home Textiles Export Cou...Dr.Mahmoud Abbas
Egyptian Textiles Export
Opportunities & Requirements
Presentation by Engineer Hany Salam, CEO Salam Textiles, Board member Egypt Textiles & Home Textiles
Export Council (THTEC)
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
1. Weaning and Extubation:
A Pediatric Perspective
Ira M. Cheifetz, MD, FCCM, FAARC
Professor of Pediatrics
Chief, Pediatric Critical Care
Medical Director, PICU & Peds Resp Care
Duke Children’s Hospital
2. Weaning and Extubation
‘The separation of a patient from his
ventilator is very nearly pure art.’
– Donald F. Egan, 1977
‘Fundamentals of Respiratory Therapy’
3. Definitions
Weaning: transition from ventilatory support
to complete spont breathing
Success: maintaining effective gas
exchange with complete spont breathing
Failure: inability to sustain effective gas
exchange w/o mechanical support within
48 hours of extubation
4. Definitions
Spontaneous breathing trial (SBT)
– test of the ability to maintain complete
spontaneous breathing (i.e., extubation
readiness)
– failure is the inability to maintain effective gas
exchange with a RR within acceptable limits
5. Indications for Weaning
Improving underlying disease process
‘Adequate’ gas exchange
No undue burden on respiratory muscles
– cardiac insufficiency
– significant hyperinflation
– severe malnutrition
– multiorgan system dysfunction / failure
Patient is capable of sustaining spontaneous
ventilation as ventilator support is decreased.
6. Effort of Breathing
Respiratory rate
Spontaneous tidal volume
WOB
– paradoxical breathing / retractions
– esophageal manometry
Inspiratory pressure of a spont breath (Pi)
Maximal negative insp pressure (NIF)
O2 cost of breathing
7. Factors that Contribute to Insp WOB
ETT size / ventilator circuit deadspace
Demand valves in the circuit
Patient - ventilator dys-synchrony
Trigger: pressure vs. flow
Distal vs. proximal sensing (??)
Any additional load on resp muscles
8. Adequacy of Gas Exchange
Oxygenation
– PaO2/FiO2
– Oxygenation index: (FiO2 x Paw) / PaO2
– alveolar-arterial O2 gradient
– venous admixture; intrapulm shunt fraction
Ventilation
– PaCO2
– physiological dead space
– EtCO2 - PaCO2 difference
– Fraction of ventilation provided by the vent
9. Vent Mode and Weaning Outcome
PSV decreased duration of weaning
– Brochard, Am J Resp Crit Care Med, 1994
Multicenter center study in adults:
– Esteban, N Engl J Med, 1995
– daily SBT led to extubation 3x faster than
IMV and 2x faster than PSV
– multiple daily SBTs were as successful as
a daily trial
11. Failed Extubation
– ↑ nosocomial pneumonia
– ↑ airway injury
– ↑ VILI
– ↑ LOV & LOS
– ↑ cost
– ↓ patient & family satisfaction
– mortality
Children requiring reintubation within 48 hrs
had significantly mortality than patients
successfully extubated (20% vs. 2%, p < 0.001)
Esteban, AJRCCM, 2001.
12. % spont breathing
% spont breathing
100
0
Time of extubation
Optimal Balance
Weaning time
100
% ventilator support
0
13. Should all adult pts be gradually
withdrawn from mech ventilation?
No!
Majority of adult patients who pass a SBT
are extubated within 24 hours
– Esteban, NEJM, 1995
– Brochard, AJRCCM, 1994
14. Should all peds pts be gradually
withdrawn from mech ventilation?
Answer remains: No!
PALISI: 58% of pts initially tested with a
minimal PS trial passed and were extubated
– Randolph, JAMA 2002
77% of pts who underwent a SBT passed &
were extubated without weaning
– Farias, Inten Care Med, 1998
15. Weaning Protocols
Study Date N ↓ LOV p
Kollef 1997 357 1.4 d 0.029
Ely 1996 300 1.5 d 0.001
Marelich 2000 253 2.3 d 0.0001
Kollef, CCM, 1997
Ely, AJRCCM, 1996
Marelich, Chest, 2000
16. On the other hand….
No differences between protocol & non-protocol
weaning for children.
Duration of weaning (n = 182; p=0.75)
– 2.9 days in the ‘protocol’ groups
(median 1.7 d)
– 3.2 days in the ‘no protocol’ group
(median 2.0 d)
Weaning protocols for ventilated pediatric pts
with ALI do NOT shorten LOV.
Randolph, JAMA, 2002.
21. Vd/Vt and Extubation
Elevated physiologic dead space predicts
Elevated physiologic dead space predicts
extubation failure
extubation failure
Successful extubation in a heterogeneous
Successful extubation in a heterogeneous
PICU population (p < 0.001)
PICU population (p < 0.001)
– Vd/Vt < 0.5: 24/25 (96%)
– Vd/Vt < 0.5: 24/25 (96%)
– Vd/Vt 0.5-0.65: 6/10 (60%)
– Vd/Vt 0.5-0.65: 6/10 (60%)
– Vd/Vt > 0.65: 2/10 (20%)
– Vd/Vt > 0.65: 2/10 (20%)
Hubble, CCM, 2000
22. General indications and
contraindications for extubation
Indications Contraindications
– alert or easily – obtunded
arousable – poor or absent cough
– good cough and gag or gag
– thin secretions easily – thick or copious
cleared from airway secretions requiring
– nl cardiac function frequent suctioning
– no MOSF – cardiac insufficiency
– MOSF
24. SBT Recommendations
Perform a SBT when
– FiO2 ≤ 0.40 PEEP ≤ 6 PIP ≤ 25
– sedation has been decreased or stopped
– adequate insp drive
– improvement or resolution of underlying cause
– pharmacological control of bronchoconstriction
– absence of significant resp acidosis
25. Weaning and Extubation:
Conclusions
Not all patients require weaning
Extubation readiness testing decreases
LOV
Ideal timing of extubation may still
remain more clinical art than science –
although this is changing with ERT